Acute Respiratory Distress Syndrome - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Respiratory Distress Syndrome - Pipeline Review, H1 2015', provides an overview of the Acute Respiratory Distress Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Respiratory Distress Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Acute Respiratory Distress Syndrome - Overview 10
Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis 11
Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies 12
Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes 13
Acute Respiratory Distress Syndrome - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Acute Respiratory Distress Syndrome - Products under Development by Companies 16
Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes 18
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development 19
Altor BioScience Corporation 19
BioMarck Pharmaceuticals, Ltd. 20
Faron Pharmaceuticals Oy 21
FirstString Research, Inc. 22
GlaxoSmithKline plc 23
Histocell S.L. 24
Mallinckrodt plc 25
Myelo Therapeutics GmbH 26
Navigen Pharmaceuticals, Inc. 27
Phylogica Limited 28
Serendex Pharmaceuticals A/S 29
Therabron Therapeutics, Inc. 30
Therametrics holding AG 31
Acute Respiratory Distress Syndrome - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ALT-836 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BIO-10901 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CG-367 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
corticotropin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DasKloster-0141-01 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DasKloster-1000-04 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
dilmapimod - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GSK-2586881 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
GSK-2862277 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
interferon beta-1a - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
molgramostim - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Monoclonal Antibody to Inhibit E-selectin for Acute Respiratory Distress Syndrome - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Myelo-001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
perfluorocarbon - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PYC-35 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
PYC-36 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PYC-38 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PYC-98 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
S-1229 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Slit2N - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Stromal Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Acute Respiratory Distress Syndrome - Recent Pipeline Updates 73
Acute Respiratory Distress Syndrome - Dormant Projects 77
Acute Respiratory Distress Syndrome - Discontinued Products 79
Acute Respiratory Distress Syndrome - Product Development Milestones 80
Featured News & Press Releases 80
Dec 20, 2013: Faron receives scientific advise from the EMA on the FP-1201-lyo clinical development 80
Oct 22, 2013: Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome 80
Nov 29, 2012: Faron Pharma Receives €6m Grant From European Commission For Traumakine Program 81
May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 AmericanThoracic Society Meeting 81
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 82
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 82
Apr 12, 2011: Faron Completes Recruitment For Phase I/II Clinical Trial Of FP-1201 83
Jan 17, 2011: Rentschler And Faron Pharma Sign Manufacturing And Supply Agreement For Traumakine 83
Sep 16, 2010: Faron's Lead Product FP-1201 Enters Next Phase Of Study 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2015 10
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Development by Companies, H1 2015 (Contd..1) 17
Products under Investigation by Universities/Institutes, H1 2015 18
Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H1 2015 19
Acute Respiratory Distress Syndrome - Pipeline by BioMarck Pharmaceuticals, Ltd., H1 2015 20
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2015 21
Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H1 2015 22
Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline plc, H1 2015 23
Acute Respiratory Distress Syndrome - Pipeline by Histocell S.L., H1 2015 24
Acute Respiratory Distress Syndrome - Pipeline by Mallinckrodt plc, H1 2015 25
Acute Respiratory Distress Syndrome - Pipeline by Myelo Therapeutics GmbH, H1 2015 26
Acute Respiratory Distress Syndrome - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 27
Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H1 2015 28
Acute Respiratory Distress Syndrome - Pipeline by Serendex Pharmaceuticals A/S, H1 2015 29
Acute Respiratory Distress Syndrome - Pipeline by Therabron Therapeutics, Inc., H1 2015 30
Acute Respiratory Distress Syndrome - Pipeline by Therametrics holding AG, H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Stage and Target, H1 2015 34
Number of Products by Stage and Mechanism of Action, H1 2015 36
Number of Products by Stage and Route of Administration, H1 2015 38
Number of Products by Stage and Molecule Type, H1 2015 40
Acute Respiratory Distress Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 73
Acute Respiratory Distress Syndrome - Dormant Projects, H1 2015 77
Acute Respiratory Distress Syndrome - Dormant Projects (Contd..1), H1 2015 78
Acute Respiratory Distress Syndrome - Discontinued Products, H1 2015 79